Fisher & Paykel Healthcare Corporation Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FSPKF research report →
Companywww.fphcare.com
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system.
- CEO
- Lewis G. Gradon
- IPO
- 2001
- Employees
- 6,978
- HQ
- Auckland, NZ
Price Chart
Valuation
- Market Cap
- $12.07B
- P/E
- 47.23
- P/S
- 9.51
- P/B
- 9.99
- EV/EBITDA
- 28.79
- Div Yield
- 1.27%
Profitability
- Gross Margin
- 63.58%
- Op Margin
- 27.17%
- Net Margin
- 20.10%
- ROE
- 22.50%
- ROIC
- 19.03%
Growth & Income
- Revenue
- $1.28B · -27.18%
- Net Income
- $377.20M · 184.46%
- EPS
- $0.64 · 178.26%
- Op Income
- $-371,000,000
- FCF YoY
- 391.83%
Performance & Tape
- 52W High
- $25.69
- 52W Low
- $16.35
- 50D MA
- $21.51
- 200D MA
- $20.84
- Beta
- 0.85
- Avg Volume
- 311
Get TickerSpark's AI analysis on FSPKF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FSPKF Coverage
We haven't published any research on FSPKF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FSPKF Report →